V 512
Alternative Names: Influenza virus vaccine - Merck; V512Latest Information Update: 23 Mar 2010
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 29 Jan 2008 Phase-I development is ongoing
- 31 Aug 2005 Phase-I clinical trials in Influenza virus infections in USA (unspecified route)